Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data

Stephanie Coward,1,2 Fiona Clement,2 Eric I. Benchimol,1,3,4,5 Charles N. Bernstein,1,6 J. Antonio Avina-Zubieta,7 Alain Bitton,1,8 Mathew W. Carroll,1,9 Glen Hazlewood,2 Kevan Jacobson,1,10 Susan Jelinski,9,11 Rob Deardon,2 Jennifer L. Jones,1,12 M. Ellen Kuenzig,1,3,4,5 Desmond Leddin,1,13 Kerry A. McBrien,2 Sanjay K. Murthy,1,4,5,14 Geoffrey C. Nguyen,1,5,15,16 Anthony R. Otley,1,12 Remo Panaccione,2 Ali Rezaie,17 Greg Rosenfeld,1,7 Juan Nicolás Peña-Sánchez,1,18 Harminder Singh,1,6 Laura E. Targownik,1,6 and Gilaad G. Kaplan1,12

1Canadian Gastro-Intestinal Epidemiology Consortium, Canada; 2University of Calgary, Calgary, Alberta, Canada; 3Children’s Hospital of Eastern Ontario IBD Centre and CHEO Research Institute, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada; 4University of Ottawa, Ottawa, Ontario, Canada; 5ICES, Toronto, Ontario, Canada; 6University of Manitoba, Winnipeg, Manitoba, Canada; 7Arthritis Research Canada, University of British Columbia, Vancouver, British Columbia, Canada; 8McGill University, Montreal, Quebec, Canada; 9University of Alberta, Edmonton, Alberta, Canada; 10British Columbia Children’s Hospital, BC Children’s Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada; 11Alberta Health Services, Edmonton, Alberta, Canada; 12Dalhousie University, Halifax, Nova Scotia, Canada; 13University of Limerick, Limerick, Ireland; 14The Ottawa Hospital Research Institute and IBD Centre, Ottawa, Ontario, Canada; 15Mount Sinai Hospital, Toronto, Ontario, Canada; 16University of Toronto, Toronto, Ontario, Canada; 17Cedar Sinai Medical Center, Los Angeles, California; and 18University of Saskatchewan, Saskatoon, Saskatchewan, Canada

BACKGROUND & AIMS: Inflammatory bowel diseases (IBDs) exist worldwide, with high prevalence in North America. IBD is complex and costly, and its increasing prevalence places a greater stress on health care systems. We aimed to determine the past current, and future prevalences of IBD in Canada. METHODS: We performed a retrospective cohort study using population-based health administrative data from Alberta (2002–2015), British Columbia (1997–2014), Manitoba (1990–2013), Nova Scotia (1996–2009), Ontario (1999–2014), Quebec (2001–2008), and Saskatchewan (1998–2016). Autoregressive integrated moving average regression was applied, and prevalence, with 95% prediction intervals (PIs), was forecasted to 2030. Annual average percentage change, with 95% confidence intervals, was assessed with log binomial regression. RESULTS: In 2018, the prevalence of IBD in Canada was estimated at 725 per 100,000 (95% PI 716–735) and annual average percent change was estimated at 2.86% (95% confidence interval 2.80%–2.92%). The prevalence in 2030 was forecasted to be 981 per 100,000 (95% PI 963–999): 159 per 100,000 (95% PI 133–185) in children, 1118 per 100,000 (95% PI 1069–1168) in adults, and 1370 per 100,000 (95% PI 1312–1429) in the elderly. In 2018, 267,983 Canadians (95% PI 264,579–271,387) were estimated to be living with IBD, which was forecasted to increase to 402,853 (95% PI 395,466–410,240) by 2030. CONCLUSION: Forecasting prevalence will allow health policy makers to develop policy that is necessary to address the challenges faced by health systems in providing high-quality and cost-effective care.

Keywords: Crohn Disease; Ulcerative Colitis; Epidemiology; Forecast Modeling.
WHAT YOU NEED TO KNOW

BACKGROUND AND CONTEXT
The prevalence of Inflammatory Bowel Disease (IBD) in Canada is among the highest in the world and is steadily increasing. However, it is unclear how much the prevalence will increase in the future.

NEW FINDINGS
In forecasting models, the prevalence of IBD, Crohn’s disease, and ulcerative colitis are significantly increasing – with some of the highest rates of increase seen within the pediatric and the elderly populations.

LIMITATIONS
This comprehensive analysis encompassing of 95% of the Canadian population lacks the ability to adjust for possible risk factors (eg, smoking) that affect the risk of developing IBD.

IMPACT
We are at a time where defining the future prevalence of disease – to 2030 – is of paramount importance as it will allow us to prepare for the impending burden.

The present study aimed to forecast the future prevalence of IBD in Canada. The Canadian population is ideal for this study because Canada has a very high prevalence of IBD and places a large burden on the single-payer health care system, making it even more important to forecast future changes. Estimating the total number of people diagnosed with IBD will allow health care providers to proactively implement clinical practices and policy interventions to address the impact of the increasing prevalence of IBD.

Methods
Study Population and Data Sources
The Canadian Gastrointestinal Epidemiology Consortium (CanGIEC) is a national collaboration of provincial IBD surveillance cohorts derived from administrative health care databases (Appendix 1). CanGIEC provided retrospective population-based provincial prevalence data of all individuals who qualify for health care, of any age, for Alberta (AB; 2002–2015), British Columbia (BC; 1997–2014), Manitoba (MB; 1990–2013), Nova Scotia (NS; 1996–2009), Ontario (ON; 1999–2014), Quebec (QC; 2001–2008), and Saskatchewan (SK; 1998–2016). These provinces account for approximately 95% of the Canadian population.7

Provincial Estimates
The prevalence of IBD, CD, and UC were calculated for each province based on years of available data from the provincial administrative health care databases listed earlier using population values from Statistics Canada (eg, AB historical analysis was from 2002 to 2015 and forecasted from 2016 to 2030).7 Prevalence rates for each year were standardized for age and sex based on the Canadian population for the associated year.7

National Estimates
Canadian population models were calculated by combining the prevalence for the 7 provinces together from 2002 to 2008—these were the only overlapping years when data were available from all provinces. Secondary analyses included sex stratification (male and female) and age stratification into pediatric (AB, BC, MB, ON, QC, and SK: 0–17 years; NS: 0–19 years), adult (AB, BC, MB, ON, QC, and SK: 18–59 years; NS: 20–59 years), and elderly (all provinces: ≥60 years) groups.

Statistical Analysis
The primary forecasting analysis was completed using autoregressive integrated moving average (ARIMA) models.8–10 An ARIMA model is a time series model in which the value being assessed is related back to historical values from periods before the current one; this is a method that has been used in econometric and prevalence forecasting.8–11 This model was chosen because of its ability to analyze data at a specific period and relate those back to data contained in prior periods while accounting for innate dependence in yearly prevalence data. An ARIMA model is used for the analysis of equidistant, and discrete samples of data in a time series model, which is necessary with the analysis of prevalence data.9,10 The ARIMA is composed of 3 components (1) autoregressive (AR), model (2) integrated, term and (3) moving average (MA) model.9,11

The AR model relates the value in a period to historical ones; the integrated term deals with the assumption of stationarity (that the probability distribution, mean and variance, remains constant over time); and the MA model relates the value back to historical residuals.9–11

First, the AR term, which integrates the prior values into the current one, can be evaluated using the partial autocorrelation function, delineating the possible lag periods that are to be included in the AR model. There can be more than 1 possibility, and the appropriate AR term is chosen in conjunction with the MA value. Second, the integrated term deals with the stationarity aspect of the data, which is evaluated using the Dickey-Fuller test.10,11 If there is a lack of stationarity, then differencing is undertaken in an attempt to achieve stationarity.11 In the present study, when differencing did not achieve stationarity, a log binomial model was used. Log binomial models analyze dichotomous outcomes, similar to logistic regression, but report outcomes as risk rather than odds. With the exception of the pediatrics and ON groups, all populations achieved stationarity, although the elderly group required differencing to achieve stationarity. Third, the MA term is evaluated with an autocorrelation function and, similar to the AR term, can have multiple possible values. Although the AR term and MA term have multiple possible values, and therefore numerous combinations of values, individual models of each possible value are created and evaluated for best fit. The best fitting models were chosen using a combination of the lowest Akaike information criterion, Bayesian information criterion, and root mean square error from each AR–MA combination. If a clear delineation between 2 models could not be made based on these criteria, then a visual inspection of the graph was used (ie, if one of the competing models displayed an incongruous narrowing prediction interval [PI]).

Once the model was selected, prevalence was forecasted. Forecasting was done using a simulation projected to 2030. Prevalence (per 100,000 persons) was forecasted to 2030, and
Sensitivity Analyses

Four sensitivity analyses were conducted. The first analysis used log binomial models instead of ARIMA. The second sensitivity analysis used ARIMA to contrast the total number of people with IBD (ie, total count) with the calculated prevalence (ie, per 100,000). These first 2 sensitivity analyses were done to assess the validity of the results from the primary analysis. The third sensitivity analysis evaluated provinces with validated coding algorithms for their study populations (AB, MB, and ON); this was done to assess the extent of misclassification bias from provinces with non-validated algorithms. The prevalence for Canada was evaluated using a longer period (2002–2013) to assess the effect that a longer period has on these estimates. In this last sensitivity analysis, NS and QC were removed because data were not available for those provinces for the full 12-year period.

Results

Provincial Analyses

The age- and sex-standardized prevalence of IBD across Canada in 2008 ranged from 445 per 100,000 in QC to 768 per 100,000 in NS (Table 1). The forecasted prevalence of IBD in 2018 for each province ranged from 652 per 100,000 (95% PI 619–686) in MB to 1224 per 100,000 (95% PI 1156–1292) in NS (Table 1 and Figure 1). In 2030, the forecasted prevalence of IBD ranged from 819 per 100,000 (95% PI 723–917) in MB to 1657 per 100,000 (95% PI 1531–1783) in NS (Table 1 and Figure 1). Figure 1 presents the annual actual prevalence of IBD for each province followed by the forecasted prevalence, with associated 95% PI. The forecasted prevalence average annual percentage changes ranged from 2.00% (95% CI 1.29–2.61) in MB to 3.89% (95% CI 3.85–3.94) in ON (Table 1 and Figure 1).

National Analyses

In 2008, the calculated prevalence of IBD in Canada was 510 per 100,000, with CD at 263 per 100,000 and UC at 226 per 100,000 (Table 1 and Figure 2), which equates to 169,564 individuals with IBD. In 2018, the prevalence in Canada was estimated at 725 per 100,000 (95% PI 716–735) for IBD, 368 per 100,000 (95% PI 363–373) for CD, and 322 per 100,000 (95% PI 318–326) for UC; this equates to 267,983 (95% PI 264,579–271,387) individuals with IBD, 135,899 (95% PI 134,065–137,734) with CD, and 118,918 (95% PI 117,424–120,412) with UC (Table 1 and Figure 2).

The average annual percentage change of IBD prevalence in Canada was estimated at 2.86% (95% CI 2.80–2.92; Table 1). The forecasted IBD prevalence in 2030 was 981 per 100,000 (95% PI 963–999), including 493 per 100,000 (95% PI 483–502) with CD and 436 per 100,000 (95% PI 428–444) with UC (Table 1 and Figure 2). The total number of individuals with IBD in 2030 was forecasted at 402,853 (95% PI 395,466–410,240) with IBD, 202,216 (95% PI 198,299–206,133) with CD, and 178,909 (95% PI 175,635–182,184) with UC (Table 1).

When stratifying the population by sex, the male prevalence of IBD was 477 per 100,000 persons in 2008, increasing to 682 per 100,000 persons (95% PI 671–692) in 2018 and 925 per 100,000 persons (95% PI 905–946) in 2030 (Table 1 and Figure 2). The female prevalence showed similar trends, with a prevalence of 542 per 100,000 persons in 2008, 768 per 100,000 persons (95% PI 758–779) in 2018, and 1036 per 100,000 persons (95% PI 1017–1055) in 2030. These 2030 prevalence estimates equate to approximately 188,326 male persons (95% PI 184,110–192,542) and 214,402 female persons (95% PI 210,487–218,317) with IBD (Table 1 and Figure 2). When stratified by age group, the 2008 prevalence of IBD was 62 per 100,000 in children, 622 per 100,000 in adults, and 646 per 100,000 in the elderly (Table 1 and Figure 3). In 2030, the estimated prevalence of IBD was 159 per 100,000 (95% PI 133–185) in children, 1118 per 100,000 (95% PI 1069–1168) in adults, and 1370 per 100,000 (95% PI 1312–1429) in the elderly (Table 1 and Figure 3). These prevalence estimates equate to approximately 12,647 children (95% PI 10,592–14,702), 238,915 adults (95% PI 228,267–249,563), and 160,736 elderly adults (95% PI 153,898–167,574) living with IBD in 2030 (Table 1 and Figure 3). All estimates for CD and UC by sex or age group are presented in Table 1.

Sensitivity Analyses

The first sensitivity analysis using log binomial regression yielded a forecasted IBD prevalence in 2018 at 828 per 100,000 (95% PI 816–839), with an increase to 1459 per 100,000 (95% PI 1421–1497) in 2030 (Appendix 2).

The second sensitivity analysis performed on the total count compared with the calculated prevalence (per 100,000) showed prevalence values that were marginally lower than those found in the primary analysis; this resulted in a forecasted 2030 prevalence of 856 per 100,000 (95% PI 835–876) for all IBD cases, 493 per 100,000 (95% PI 483–502) for CD, and 380 per 100,000 (95% PI 372–388) for UC (see Appendix 2 for further details).

The third sensitivity analysis, using only provinces with validated algorithms, forecasted a prevalence of IBD at 909 per 100,000 (95% PI 842–976) in 2030 (Appendix 2); this 95% PI overlaps with the 95% PI in the primary analysis, suggesting similar results from the primary and sensitivity analyses (Table 1 and Appendix 2).

The fourth sensitivity analysis, removing NS and QC from the model to allow for a longer period of analysis, resulted in values similar to those seen in the
Table 1. Actual and Forecasted Prevalence, Including AAPC, Stratified by Province and Age

| Sex stratification | Sex stratification | Sex stratification | Sex stratification | Sex stratification | Sex stratification | Sex stratification | Sex stratification | Sex stratification | Sex stratification | Sex stratification |
|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| IBD                | CD                 | UC                 | IBD                | CD                 | UC                 | IBD                | CD                 | UC                 | IBD                | CD                 | UC                 |
| Standardized       | Forecasted         | Forecasted         | Standardized       | Forecasted         | Forecasted         | Standardized       | Forecasted         | Forecasted         | Standardized       | Forecasted         | Forecasted         |
| prevalence         | prevalence         | AAPC,              | prevalence         | prevalence         | prevalence         | prevalence         | prevalence         | prevalence         | prevalence         | prevalence         | prevalence         |
| per 100,000        | per 100,000        | % (95% CI)         | per 100,000        | per 100,000        | % (95% CI)         | per 100,000        | per 100,000        | % (95% CI)         | per 100,000        | per 100,000        | % (95% CI)         |
| MB                 | 567                | 652 (619–686)      | 819 (723–917)      | 2.00 (1.29–2.61)   | 283                | 316 (299–333)      | 390 (340–439)      | 1.84 (1.07–2.49)   | 285                | 338 (321–356)      | 433 (384–483)      | 2.18 (1.51–2.75)   |
| NS                 | 870                | 1224 (1156–1292)   | 1657 (1531–1783)   | 2.86 (2.55–3.14)   | 412                | 554 (522–587)      | 728 (667–789)      | 2.55 (2.20–2.86)   | 350                | 503 (474–532)      | 692 (634–750)      | 3.03 (2.68–3.34)   |
| ON                 | 507                | 731 (728–735)      | 1156 (1144–1169)   | 3.89 (3.85–3.94)   | 243                | 335 (322–337)      | 500 (493–508)      | 3.40 (3.34–3.47)   | 247                | 363 (360–365)      | 591 (582–600)      | 4.16 (4.09–4.22)   |
| SK                 | 555                | 636 (606–666)      | 893 (707–1080)     | 2.89 (1.29–4.13)   | 316                | 358 (343–373)      | 491 (399–583)      | 2.69 (1.26–3.82)   | 239                | 279 (264–294)      | 403 (313–493)      | 3.13 (1.41–4.43)   |
| All                | 510                | 725 (716–735)      | 981 (963–999)      | 2.86 (2.80–2.92)   | 263                | 368 (363–373)      | 493 (483–502)      | 2.75 (2.69–2.81)   | 226                | 322 (318–326)      | 436 (428–444)      | 2.87 (2.81–2.93)   |
| Pediatric (<18)    | Female             | 542                | 768 (758–779)      | 1036 (1017–1055)   | 2.83 (2.77–2.88)   | 296                | 409 (403–415)      | 542 (531–554)      | 2.65 (2.59–2.72)   | 224                | 321 (317–325)      | 437 (429–445)      | 2.92 (2.87–2.98)   |
| Adult (18–59)      | Male               | 477                | 682 (671–692)      | 925 (905–946)      | 2.89 (2.82–2.97)   | 229                | 326 (321–331)      | 441 (432–450)      | 2.87 (2.80–2.94)   | 229                | 323 (319–327)      | 435 (426–443)      | 2.81 (2.75–2.88)   |
| Elderly (≥60)      | 62                 | 96 (88–104)        | 159 (133–185)      | 4.32 (3.57–4.93)   | 40                 | 58 (52–64)         | 91 (72–109)        | 3.76 (2.81–4.50)   | 19                 | 29 (25–34)         | 51 (35–66)         | 4.59 (3.05–5.66)   |
|                    | 622                | 849 (823–876)      | 1118 (1069–1168)   | 2.59 (2.43–2.74)   | 336                | 453 (430–476)      | 590 (547–633)      | 2.48 (2.24–2.70)   | 262                | 357 (351–364)      | 470 (457–483)      | 2.56 (2.47–2.65)   |

AAPC, average annual percentage change.

aYounger than 18 years for AB, BC, MB, ON, QC, and SK and <20 years for NS.

bFrom 18 to 59 years for AB, BC, MB, ON, QC, and SK and 20 to 59 for NS.
primary analysis, with an IBD prevalence estimate of 700 per 100,000 (95% PI 680–719) in 2018 and 931 per 100,000 (95% PI 882–980) in 2030 (Appendix 2). An interactive web-based map describing the prevalence of IBD across Canada from 2002 to 2030 is available at this link: https://people.ucalgary.ca/~ggkaplan/IBDCPREV.html.

**Discussion**

We conducted a nationwide study using historical population-based data from 7 provinces to estimate the current, and forecast the future, prevalence of IBD. In 2008, approximately 0.5% of the Canadian population had IBD; by 2018, prevalence was estimated at 0.7%; and, by 2030, it

![Figure 1](https://people.ucalgary.ca/~ggkaplan/IBDCPREV.html)

**Figure 1.** Actual and forecasted prevalence of IBD in Canada by province. Actual prevalence, standardized for age and sex, is denoted by the *solid line*. Forecasted prevalence—analyzed with an ARIMA model and then forecasted until 2030—is indicated by a *dashed line* with the PI highlighted in *gray*. For an interactive map please see https://people.ucalgary.ca/~ggkaplan/IBDCPREV.html.

![Figure 2](https://people.ucalgary.ca/~ggkaplan/IBDCPREV.html)

**Figure 2.** Actual and forecasted prevalence of IBD in male and female patients and total patients in Canada. Actual prevalence, standardized for age and sex, is denoted by the *solid line* and prevalence is calculated through summation of total affected individuals and total population from each province. Forecasted prevalence—analyzed with an ARIMA model and then forecasted until 2030—is indicated by a *dashed line* with the PI highlighted in *gray*.
was forecasted to increase to 1.0%. We estimate that approximately 270,000 Canadians are currently living with IBD and that, by 2030, the Canadian health care systems might be caring for more than 402,000 patients with IBD. Prevalence is increasing in all age groups, but particularly among the elderly because of newly diagnosed seniors and the advancing age of patients with previously diagnosed IBD. Ambulatory clinics in 2030 will be distinctly different from current clinics as health care providers contend with caring for considerably more patients with IBD—including younger newly diagnosed patients and older patients with longer disease duration and comorbidities of advancing age.

The prevalence of IBD is forecasted to increase steadily by 2.86% per year in Canada. As a lifelong disease without a cure, the compounding prevalence of IBD is due to the disparity between incidence and mortality. Because changes in incidence are inherently captured within our models of changing prevalence (a combination of new cases, current cases, and cases removed from the population), we did not separately analyze incidence. As long as the incidence exceeds the mortality, our clinics will continue to add newly diagnosed patients on the foundation of our previously diagnosed patients every year. However, future studies accounting for life expectancy are necessary to establish the threshold that incidence needs to decrease for prevalence to stabilize. Nonetheless, these data should serve as a clarion call to health care systems to prepare their infrastructure, personnel, and resources to manage the rising burden of IBD.

With 95% of the Canadian population represented by our study, the findings are generalizable to other westernized nations with similar rates and demographics of IBD. For example, similar to Canada, the prevalence of IBD is increasing steadily in the United States. A series of studies documenting this trend in Olmsted County, Minnesota was published using data ranging from 1940 to 2010. In 2001, the prevalence of IBD in Olmsted County was 388 per 100,000 and increased to 533 per 100,000 in 2010; this equates to an estimated 1.64 million individuals living with IBD as of 2010 in the United States. If the prevalence increases to the same level as in Canada—0.98% in 2030—more than 3.48 million individuals could have IBD in the United States, more than double the 2010 estimate.
Moreover, similar trends of rising prevalence have been observed in Europe and Australia. Thus, a strategy to address the compounding prevalence of IBD in the Western world is necessary. Although our data are less applicable outside the Western world, where prevalence of IBD remains low, the rapidly increasing incidence of IBD in newly industrialized countries in Asia and Latin America suggests that these countries might begin to experience compounding prevalence analogous to the Western world in a generation from now.

Although the exact future prevalence of IBD is unknown, it is apparent that the prevalence will continue to increase—so, how do health care systems adapt? By bringing awareness of this impending burden to the public and physicians alike, we can increase community engagement and bring this disease to the forefront of policy makers’ agendas. This awareness could lead to an influx of funding for laboratory and epidemiologic research, which in turn will aid in preventing disease by furthering the knowledge base and thus working to lower the incidence of disease. If we cannot prevent new cases of IBD, then the forecasted increases in prevalence will lead to increased overall costs to health care systems, especially with medications, some of which can exceed tens of thousands of dollars per year per individual. Identifying the current drivers of cost and projecting the costs into the future are paramount to being able to define the future burden of disease, evaluate the future impact on health care systems, and ensure access and affordability. Further, developing alternative care pathways (eg, nurse practitioners) will help to ensure that those with IBD still receive the necessary care without health care systems being overwhelmed.

This study forecasts the future prevalence of IBD, but it is not without limitations. Heterogeneity in prevalence was observed between provinces. NS had the highest prevalence of IBD. Because NS is the only Atlantic province in the dataset, we could not assess whether the high prevalence value was representative of the east coast of Canada or unique to NS. Heterogeneity between provinces can be explained by inherent differences between populations, such as demography, genetic penetrance, and environmental exposures associated with IBD (eg, diet). The models do not directly account for future variations in environmental risk factors (eg, breastfeeding or smoking) that can influence incidence, because these data were not available at the individual level for this cohort. Further, because prevalence was calculated using administrative health care databases, possible misclassification errors in the diagnosis of IBD can occur. To overcome this, AB, MB, and ON use validated algorithms, which ensure accuracy of the data based on sensitivity, specificity, and predictive values of diagnostic codes. The other provinces have applied these algorithms without cross-referencing accuracy with chart reviews. However, our sensitivity analysis—evaluating only the provinces with validated algorithms—produced prevalence estimates consistent with our main analyses. Also, our national estimates of IBD include all patients with IBD; however, 5.6% of patients have unclassified IBD. These patients have IBD, but the algorithm used to distinguish CD from UC cannot differentiate the specific subtype. In consequence, the CD and UC stratified analyses do not account for these individuals. In addition, provinces report different timeframes based on available data: MB contains the longest period (1990–2013) and QC contains the shortest (2001–2008). Thus, our primary national model was restricted to 2002–2008 that included prevalence data from all 7 provinces. However, a sensitivity analysis of 5 provinces with prevalence data spanning 2002–2013 yielded similar estimates on forecasted prevalence (931 per 100,000 in 2030) compared with our primary national model (981 per 100,000). Further, there is an inherent uncertainty associated with forecast modeling because the methodology forecasts future values that are yet unknown based on an assumption that historical trends (eg, incidence rates) will be similar in the future. To address this, PIs are created that acknowledge this uncertainty and give a range of possible values for the true prevalence. The use of the best fitting models also mitigates this limitation by ensuring that forecasting models are true to the current data. Moreover, sensitivity analyses using alternate forecasting approaches (ie, log binomial modeling) yield similar estimates.

Forecasting the number of people with IBD alone is insufficient in defining the overall burden of IBD. We anticipate that the future landscape of IBD will evolve: increased use of biologics and new therapies in the pipeline, decreasing rates of hospitalization and surgery, and unpredictability of a landmark discovery, including a potential cure. Future studies are necessary to integrate rising prevalence with other clinical factors that influence the burden of IBD to the health care system.

Overall, the future prevalence of IBD will lead to an increased stress on health care systems. We are at a time when new policies and innovations in the delivery of IBD care can help ensure that the nearly 4 million patients with IBD in North America (by 2030) will continue to receive the necessary care in the future. If health care systems fail to adjust for the impending burden of IBD, then they will be overwhelmed, and patients might not receive the care they need.

**Supplementary Material**

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at www.gastrojournal.org, and at https://doi.org/10.1053/j.gastro.2019.01.002.

**References**


3. Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory


13. Stata version 14 [computer program]. College Station, TX: StataCorp, 2015.


Author names in bold designate shared co-first authorship.

Received July 21, 2018. Accepted January 2, 2019.

Reprint requests
Address requests for reprints to: Gilaad G. Kaplan, MD, MPH, FRCP, Teaching Research and Wellness Building, 3D03-18, 3280 Hospital Drive NW, Calgary, Alberta, T2N 4C6, Canada. e-mail: ggkaplan@ucalgary.ca.

Acknowledgments
Disclaimer: This study is based in part on de-identified data provided by Alberta Health Services, Régie de l’assurance maladie du Québec, Ministry of Health of British Columbia and Population Data BC, Saskatchewan Ministry of Health, Health Data Nova Scotia of Dalhousie University, and Manitoba Health. The interpretation and conclusions contained herein are those of the researchers and do not necessarily represent the views of the Government of Alberta, Government of Quebec, Government of British Columbia, Government of Saskatchewan or the Ministry of Health, Health Data Nova Scotia or the Department of Health and Wellness, or the Government of Manitoba. Neither the Government of Alberta nor Alberta Health Services expressed any opinion in relation to this study. This study was supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Ministry of Health. Although this research and health service assessment analysis is based on data obtained from the Nova Scotia Department of Health and Wellness, the observations and opinions expressed are those of the authors and do not represent those of Health Data Nova Scotia or the Government of Saskatchewan. An interactive web-based map describing the prevalence of IBD across Canada from 2002 to 2030 is available at this link: https://people.ualberta.ca/~ggkaplan/IBDPREV.html.

Author contributions: Stephanie Coward contributed to study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; and statistical analysis. Fiona Clement, Charles N. Bernstein, Mathew W. Carroll, Glen Hazlewood, Kevan Jacobson, M. Ellen Kuenzig, Desmond Leddin,
Kerry A. McBrien, Sanjay K. Murthy, Remo Panaccione, Ali Rezaie, and Harminder Singh contributed to study design and critical revision of the manuscript for important intellectual content. Eric I. Benchimol, J. Antonio Avina-Zubieta, Alain Bitton, Susan Jelinski, Jennifer L. Jones, Geoffrey C. Nguyen, Anthony R. Otley, Greg Rosenfeld, Juan Nicolás Peña-Sánchez, and Laura E. Targownik contributed to study design, data acquisition, critical revision of the manuscript for important intellectual content, and obtained funding. Rob Deardon and Ali Rezaie contributed to study design, interpretation of data, and critical revision of the manuscript for important intellectual content. Gilaad G. Kaplan contributed to study concept and design; acquisition of data; interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; obtained funding; administrative, technical, or material support; and study supervision.

**Conflicts of interest**

Charles N. Bernstein been on the advisory boards for AbbVie Canada, Ferring Canada, Janssen Canada, Shire Canada, Takeda Canada, Pfizer Canada, and Napo Pharmaceuticals; consulted to 4D Pharma and Mylan Pharmaceuticals; has received educational grants from AbbVie Canada, Pfizer Canada, Shire Canada, Takeda Canada, Janssen Canada; and has been on the speaker’s panel for Ferring Canada, Medtronic Canada, and Shire Canada. Harminder Singh is on an advisory board for Merck Canada, Ferring Canada and has a research grant from Merck Canada. Laura E. Targownik is on the advisory board for Takeda, Janssen, AbbVie, Merck, Pfizer, and Ferring; received research funds from Janssen; and is a speaker for Takeda, Janssen, and AbbVie. Gilaad G. Kaplan has served as a speaker for Janssen, AbbVie, and Pfizer and has received research support from Janssen, AbbVie, GlaxoSmithKline, and Shire. Stephanie Coward, Alain Bitton, Anthony R. Otley, Ali Rezaie, Desmond Leddin, Eric I. Benchimol, Fiona Clement, Glen Hazlewood, Geoffrey C. Nguyen, Greg Rosenfeld, J. Antonio Avina-Zubieta, Jennifer L. Jones, Juan Nicolás Peña-Sánchez, Kerry A. McBrien, Kevan Jacobson, Matthew W. Carroll, M. Ellen Kuenzig, Remo Panaccione, Rob Deardon, Susan Jelinski, and Sanjay K. Murthy have no conflicts of interest to declare.

**Funding**

This study was supported by a CIHR Project Grant (funding reference number 153420) and a CIHR Team Grant (Health Challenges in Chronic Inflammation, grant THC-135235). The project was supported by the Digestive Health Strategic Clinical Network, Alberta Health Services. Gilaad G. Kaplan is a CIHR Embedded Clinician Research Chair. Stephanie Coward is supported by an Izaak Walton Killam Doctoral Scholarship and an Eyes High Doctoral Recruitment Scholarship. Eric I. Benchimol is supported by a New Investigator Award from CIHR, Crohn’s and Colitis Canada, and the Canadian Association of Gastroenterology. Eric I. Benchimol also is supported by the Career Enhancement Program of the Canadian Child Health Clinician Scientist Program. Charles N. Bernstein is supported in part by the Bingham Chair in Gastroenterology. M. Ellen Kuenzig is supported by a CIHR Postdoctoral Fellowship.
References for Appendices


## Appendix 1. Province-Specific Overview

<table>
<thead>
<tr>
<th>Prevalent cohort availability</th>
<th>AB</th>
<th>BC</th>
<th>MB</th>
<th>NS</th>
<th>ON</th>
<th>QC</th>
<th>SK</th>
</tr>
</thead>
</table>

### Time measure
- Fiscal year (April 1–March 31)
- Calendar year (January 1–December 31)
- Mid-year (July 1)
- Fiscal year (April 1–March 31)
- Mid-year (July 1)
- Fiscal year (April 1–March 31)

### Diseases classified
- CD, UC, IBD-U, IBD
- CD, UC, IBD-U, IBD
- CD, UC, IBD-U, IBD
- CD, UC, IBD-U, IBD
- CD, UC, IBD
- CD, UC, IBD

### Identification algorithm validation reference
- Rezaie et al, 2012
- Bernstein et al, 1999
- Rezaie et al, 2012
- Rezaie et al, 2012
- Bernstein et al, 1999
- N/A

### Identification algorithm used
- AB (≥2 hospitalizations or 4 physician claims or 2 medical contacts in 2 y)
- AB (≥2 hospitalizations or 4 physician claims or 2 medical contacts in 2 y)
- MB (5 physician contacts of any combination of outpatient contacts or hospitalizations using Outpatient Physician Database or Hospitalization Database)
- AB (≥2 hospitalizations or 4 physician claims or 2 medical contacts in 2 y)
- AB (≥2 hospitalizations or 4 physician claims or 2 medical contacts in 2 y)
- MB (≥5 physician contacts or CIHI-DAD records within 2 y of health coverage, and ≥3 separate contacts with <2 y of coverage)

### Validity of identification algorithm
- Sensitivity 83.4%, positive predictive value 97.4%
- Sensitivity 74.4%–89.2%, specificity 89.8%–93.7%
- N/A
- N/A
- N/A

### Physician billing
- Alberta Health Physician Claims
- Population Data BC captures all provincially funded health care services data since 1990, including all outpatient medical visits, hospital admissions and discharges, interventions, investigations, demographic data, cancer registry, and vital statistics.
- Manitoba Health Physicians Claims database
- MSI
- OHIP
- RAMQ
- Physician Services Claims File: Medical Services Branch (MSB)
### Appendix 1. Continued

<table>
<thead>
<tr>
<th>Prevalent cohort availability</th>
<th>AB</th>
<th>BC</th>
<th>MB</th>
<th>NS</th>
<th>ON</th>
<th>QC</th>
<th>SK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hospitalization</strong> (associated with 20 diagnostic codes)</td>
<td>CIHI-DAD</td>
<td>CIHI-DAD</td>
<td>CIHI-DAD</td>
<td>CIHI-DAD</td>
<td>MedEcho</td>
<td>Hospital Discharge Abstract Database (CIHI-DAD)</td>
<td></td>
</tr>
<tr>
<td><strong>Ambulatory care</strong> (including ED visits)</td>
<td>NACRS</td>
<td>Manitoba Health Physicians Claims database</td>
<td>Only day surgery and ED visits</td>
<td>OHIP (1991–2016); NACRS (2002 onward)</td>
<td>MedEcho</td>
<td>MSB and ED visits from NACRS (CIHI NACRS, ED data)</td>
<td></td>
</tr>
<tr>
<td><strong>Basic demographic information (date of birth, eligibility, date of death)</strong></td>
<td>Manitoba Health population registry</td>
<td>Nova Scotia Vital Statistics, Insured Patient Registry</td>
<td>RPDB</td>
<td>RAMQ</td>
<td>PHRS</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sample of previously published articles using algorithm</strong></td>
<td>Frolikis et al, 201411; Kuenzig et al, 201712</td>
<td>N/A</td>
<td>Benchimol et al, 201713; Melesse et al, 201514 and 201715; Shaw et al, 2013,16 2014,17 and 201518</td>
<td>Benchimol et al, 2014,20 2014,21 and 201522; Bollegala et al, 201723; Nguyen et al, 201524</td>
<td>Bitton et al, 201425</td>
<td>Pena-Sanchez et al, 201726</td>
<td></td>
</tr>
<tr>
<td>Cases of IBD in 2008</td>
<td>18,269</td>
<td>22,937</td>
<td>6516</td>
<td>8104</td>
<td>64,963</td>
<td>35,005</td>
<td>5357</td>
</tr>
<tr>
<td>Cases of IBD in 2008 (standardized)a</td>
<td>19,039</td>
<td>22,420</td>
<td>6795</td>
<td>8143</td>
<td>65,278</td>
<td>34,567</td>
<td>5643</td>
</tr>
<tr>
<td>Population size in 2008</td>
<td>3,595,755</td>
<td>4,499,139</td>
<td>1,197,774</td>
<td>935,865</td>
<td>12,882,625</td>
<td>7,761,504</td>
<td>1,017,346</td>
</tr>
</tbody>
</table>

CIHI-DAD, Canadian Institute for Health Information–Discharge Abstract Database; ED, emergency department; IBD-U, inflammatory bowel disease–unclassified; MSB, Medical Services Billing; MSI, Medical Services Incorporated; N/A, not applicable; NACRS, National Ambulatory Care Reporting System; OHIP, Ontario Health Insurance Plan; PHRS, Person Health Registration System; RAMQ, Régie de l’assurance maladie du Québec; RPDB, Registered Persons Database.

*aNumbers presented might vary from actual numbers in the original administrative data: suppressed cells occurred in data provided by provinces, which altered the final values contained in the analysis compared with the original.

*bNumbers were standardized by age and sex based on the Canadian population.27
### Appendix 2. Sensitivity Analyses of Forecasted Prevalence and AAPC

<table>
<thead>
<tr>
<th></th>
<th>IBD</th>
<th>CD</th>
<th>UC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Forecasted prevalence</td>
<td>Forecasted prevalence</td>
<td>Forecasted prevalence</td>
</tr>
<tr>
<td></td>
<td>2018 2030</td>
<td>2018 2030</td>
<td>2018 2030</td>
</tr>
<tr>
<td></td>
<td>per 100,000 (95% PI)</td>
<td>per 100,000 (95% PI)</td>
<td>per 100,000 (95% PI)</td>
</tr>
<tr>
<td></td>
<td>Forecasted AAPC, % (95% CI)</td>
<td>Forecasted AAPC, % (95% CI)</td>
<td>Forecasted AAPC, % (95% CI)</td>
</tr>
<tr>
<td>Using population values</td>
<td>684 (673–694) 856 (835–876) 2.23 (2.13–2.32)</td>
<td>368 (363–373) 493 (483–502) 2.75 (2.69–2.81)</td>
<td>303 (300–307) 380 (372–388) 2.23 (2.15–2.32)</td>
</tr>
<tr>
<td>Canada (validated algorithms)</td>
<td>681 (661–701) 909 (842–976) 2.52 (2.09–2.91)</td>
<td>319 (307–330) 412 (376–449) 2.25 (1.71–2.74)</td>
<td>309 (289–328) 413 (357–469) 2.55 (1.74–3.23)</td>
</tr>
<tr>
<td>Canada (without NS or QC: 2002–2013)</td>
<td>700 (680–719) 931 (882–980) 2.52 (2.25–2.77)</td>
<td>327 (317–336) 425 (400–450) 2.33 (2.02–2.61)</td>
<td>328 (316–340) 438 (409–468) 2.57 (2.24–2.88)</td>
</tr>
</tbody>
</table>

AAPC, average annual percentage change.